Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
Palvella Therapeutics Awarded Up to $2.6 Million Grant From the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 Loss per Share (Vs US$3.63 Profit in 2Q 2023)
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Pieris Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.
Shareholder Alert: Ademi LLP Investigates Whether Pieris Pharmaceuticals, Inc. Has Obtained a Fair Price for Its Public Shareholders
Trending Stocks Today | Nuzee Surges 273.78%
July 24th - US stocks trending in regular trading hours.Gainers: $Nuzee(NUZE.US)$ shoots up 273.78% to $3.85 with a turnover of $404.63 million. $Dermata Therapeutics(DRMA.US)$ soars 122.31% to $2.89
Sector Update: Health Care Stocks Advance in Afternoon Trading
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
Pieris Pharma Surges on All-stock Merger Deal
Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics
Pieris Pharmaceuticals Shares Resume Trade
Pieris Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 93.2%
Traders Digest Alphabet, Tesla Results, Fueling Premarket Losses for US Equity Futures
Merger News Boosts Pieris (PIRS) Stock In Pre-Market Trading
Pieris Pharmaceuticals Shares Are Trading Higher After the Company Announced That the Company Entered Into a Definitive Merger Agreement With Palvella Therapeutics.
Top Premarket Gainers
Express News | Pieris Pharmaceuticals- Combined Company to Be Led by Wes Kaupinen & Other Members of Palvella Management Team